Mutivariable analysis of clinical and laboratory parameters
| Factor* . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) . | P† . | Hazard ratio (95% CI) . | P† . | |
| Parameters analyzed | ||||
| Sex | ||||
| Male vs female | 1.25 (0.96-1.63) | .10 | 1.18 (0.92-1.50) | .21 |
| Age at time of sampling | ||||
| ≥ 70 y vs 50-69 y vs < 50 y | 1.82 (1.49-2.23) | < .0001 | 1.68 (1.40-2.01) | < .0001 |
| MC | ||||
| Poor vs intermediate vs good | 1.61 (1.37-1.90) | < .0001 | 1.48 (1.27-1.74) | < .0001 |
| WHO risk group | ||||
| High vs low | 3.24 (2.48-4.23) | < .0001 | 3.11 (2.41-4.01) | < .0001 |
| New lesions by SNP-A | ||||
| Yes or No | 1.64 (1.27-2.12) | .0002 | 1.33 (1.05-1.68) | .02 |
| Parameters analyzed | ||||
| Sex | ||||
| Male vs female | 1.28 (0.98-1.66) | .07 | 1.19 (0.93-1.53) | .17 |
| Age at time of sampling | ||||
| ≥ 70 y vs 50-69 y vs < 50 y | 1.85 (1.51-2.27) | < .0001 | 1.69 (1.41-2.03) | < .0001 |
| MC | ||||
| Poor vs intermediate vs good | 1.58 (1.34-1.86) | < .0001 | 1.47 (1.25-1.72) | < .0001 |
| WHO risk group | ||||
| High vs Low | 3.09 (2.63-4.03) | < .0001 | 3.03 (2.35-3.90) | < .0001 |
| No. of new lesions by SNP-A | ||||
| ≥ 3 vs 1-2 vs 0 | 1.47 (1.24-1.74) | < .0001 | 1.25 (1.06-1.47) | .007 |
| Factor* . | Overall survival . | Event-free survival . | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) . | P† . | Hazard ratio (95% CI) . | P† . | |
| Parameters analyzed | ||||
| Sex | ||||
| Male vs female | 1.25 (0.96-1.63) | .10 | 1.18 (0.92-1.50) | .21 |
| Age at time of sampling | ||||
| ≥ 70 y vs 50-69 y vs < 50 y | 1.82 (1.49-2.23) | < .0001 | 1.68 (1.40-2.01) | < .0001 |
| MC | ||||
| Poor vs intermediate vs good | 1.61 (1.37-1.90) | < .0001 | 1.48 (1.27-1.74) | < .0001 |
| WHO risk group | ||||
| High vs low | 3.24 (2.48-4.23) | < .0001 | 3.11 (2.41-4.01) | < .0001 |
| New lesions by SNP-A | ||||
| Yes or No | 1.64 (1.27-2.12) | .0002 | 1.33 (1.05-1.68) | .02 |
| Parameters analyzed | ||||
| Sex | ||||
| Male vs female | 1.28 (0.98-1.66) | .07 | 1.19 (0.93-1.53) | .17 |
| Age at time of sampling | ||||
| ≥ 70 y vs 50-69 y vs < 50 y | 1.85 (1.51-2.27) | < .0001 | 1.69 (1.41-2.03) | < .0001 |
| MC | ||||
| Poor vs intermediate vs good | 1.58 (1.34-1.86) | < .0001 | 1.47 (1.25-1.72) | < .0001 |
| WHO risk group | ||||
| High vs Low | 3.09 (2.63-4.03) | < .0001 | 3.03 (2.35-3.90) | < .0001 |
| No. of new lesions by SNP-A | ||||
| ≥ 3 vs 1-2 vs 0 | 1.47 (1.24-1.74) | < .0001 | 1.25 (1.06-1.47) | .007 |
Adjusting for the factors in this table, blasts in the peripheral blood, unavailable for 22% of patients, was seen to be an additional independent predictor of overall but not event-free survival (P = .02 and .03, respectively).
Factor with the poorer prognosis is listed first.
Determined by the Wald test.